Diffuse Intrinsic Pontine Glioma (DIPG) Research
Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive, inoperable, and uniformly fatal pediatric brainstem tumor for which no treatment exists. The median survival rate for DIPG patients is about 9 months from diagnosis, and the five-year survival rate is less than one percent. This dismal prognosis makes DIPG the most devastating of all pediatric brain tumors.
The Lyssiotis lab is studying metabolic dysregulation in DIPG with the goal to identify perturbations that promote the aggressive tumor-phenotype and treatment resistance in DIPG. The primary focus of our research studies is to uncover unique metabolic dependencies in DIPG that can be targeted for therapy.
DIPG research in the Lyssiotis lab is generously funded by various organizations including: The ChadTough Foundation, The Alex’s Lemonade Stand Foundation (ALSF), and the Defeat DIPG Foundation.
Venneti lab http://www.venneti-lab.com/
Koschmann lab https://www.koschmannlab.org/
Castro lab http://castro-lowenstein.lab.medicine.umich.edu/
Targeting Increased Anaplerotic Metabolism of Pathogenic T Cells to Treat Immune Disease
Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, Liu X, Hao LY, Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer C, Boros L, Opipari AW. J. Pharmacol. Exp. Ther. (2014) 351, 298–307.
Abstract | PDF | Extended Figures